Citius Oncology, Inc.
CTOR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $1 | $3 | $1 |
| G&A Expenses | $4 | $4 | $4 | $5 |
| SG&A Expenses | $4 | $4 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $5 | $7 | $6 |
| Operating Income | -$5 | -$5 | -$7 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$5 | -$5 | -$7 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$8 | -$7 |
| % Margin | – | – | – | – |
| EPS | -0.062 | -0.075 | -0.11 | -0.093 |
| % Growth | 17.7% | 31.8% | -18.2% | – |
| EPS Diluted | -0.062 | -0.075 | -0.11 | -0.093 |
| Weighted Avg Shares Out | 81 | 72 | 72 | 72 |
| Weighted Avg Shares Out Dil | 81 | 72 | 72 | 72 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$5 | -$7 | -$6 |
| % Margin | – | – | – | – |